Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Shenzhen Bromake New Material
301387
5
Nanjing Vishee Medical Technology Co., Ltd
688580
US OptionsDetailed Quotes
GMAB250516P20000
- 0.40
- -0.20-33.33%
15min DelayClose Apr 29 16:00 ET
0.40High0.40Low
0.40Open0.60Pre Close1 Volume5.18K Open Interest20.00Strike Price40.00Turnover51.84%IV5.72%PremiumMay 16, 2025Expiry Date0.00Intrinsic Value100Multiplier17DDays to Expiry0.40Extrinsic Value100Contract SizeAmericanOptions Type-0.3374Delta0.1582Gamma37.80Leverage Ratio-0.0247Theta-0.0032Rho-12.75Eff Leverage0.0163Vega
Genmab Newsroom
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $37
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab's Strong Market Position and Growth Potential Justifies Buy Rating
Leerink Partners Maintains Genmab(GMAB.US) With Buy Rating, Announces Target Price $29
Analysts Have Conflicting Sentiments on These Healthcare Companies: Geron (GERN), Genmab (GMAB) and Elanco Animal Health (ELAN)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Barclays Reaffirms Their Buy Rating on Genmab A/S (0MGB)
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab Analyst Ratings
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Cuts Target Price to $37
Genmab's Strong Financial Performance and Strategic Positioning Justify Buy Rating Despite Minor Setbacks
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Genmab A/S Faces Sell Rating Amid Hexabody Setbacks and Darzalex Patent Concerns
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $25
Truist Financial Maintains Genmab(GMAB.US) With Buy Rating
Market Insights
Discussing
2025 Buffett shareholders' meeting: What's the new buzz in value investing?
🎙️Discussion 1. In the face of market changes, do you prefer to stick with growth stocks or switch to value stocks? 2. Based on the current
Moomoo News Global
Apr 28 18:10
Warren Buffett Stands Tall as U.S. Stocks Tumble: How the 'Oracle' Is Tackling Tariff Impacts
Discussing
FOMC holds rates amid heightened uncertainty: Where will US stocks head next?
🎙️Discussion 1. With the Fed highlighting "elevated uncertainty", are you prioritizing rate projections or near-term economic data for ma
Moo Live
Mar 20 02:25
FOMC Press Conference, March 19, 2025
U.S Tech Companies U.S Tech Companies
U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data. U.S leading technology companies with strong market presence, influential in their industries, and notable for robust innovation and profitability. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only.
This section presents the top 5 stocks in U.S Tech Companies, ranked from highest to lowest based on real-time market data.
Unlock Now